Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29877981 | 0.82 | KDM4E (0.32) | KDM4EALDH1A1POLB | |
| SCHEMBL7585113 | 0.80 | KDM4E (0.35) | KDM4EALDH1A1POLBEGLN2 | |
| SCHEMBL31728930 | 0.80 | PIK3CD (0.34) | KDM4EALDH1A1POLBEGLN2 | |
| SCHEMBL2297778 | 0.80 | KDM4E (0.46) | KDM4EALDH1A1POLB | |
| SCHEMBL20113370 | 0.79 | USP8 (0.35) | KDM4EALDH1A1POLBEGLN2 | |
| SCHEMBL29368821 | 0.79 | USP8 (0.35) | KDM4EALDH1A1POLBEGLN2 | |
| SCHEMBL21014938 | 0.72 | PIK3CD (0.34) | KDM4EALDH1A1POLB | |
| SCHEMBL25205318 | 0.71 | VRK1 (0.33) | — | |
| SCHEMBL31015996 | 0.71 | VRK1 (0.33) | — | |
| SCHEMBL3119330 | 0.71 | EGLN2 (0.40) | KDM4EALDH1A1POLBEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-25 | — | — | US | disclosed |
| EP-4337660-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| CN-117597345-A | Heterocyclic derivatives as CaMKK2 inhibitors | 百时美施贵宝公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240059680-A1 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | ELANCO TIERGESUNDHEIT AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-4247809-A2 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | Elanco Tiergesundheit AG (CH) | 2023-09-27 | — | — | EP | disclosed |
| CN-116685584-A | N- (2, 3-dihydro-1, 4-benzoxazin-4-yl) -3-isopropyl-7- (2, 3, 5-trifluorophenyl) benzothiophene-2-carboxamide derivatives and similar compounds for the treatment of heartworm infections | 礼蓝动物保健有限公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022240826-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-11466027-B2 | Modulators of the NMDA receptor | H. LUNDBECK A/S (DK) | 2022-10-11 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-9073918-B2 | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-05 | — | — | US | disclosed |
| WO-2011146287-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KDM4E 4125/4885ALDH1A1 576/4885POLB 4839/4885 |
| US-11466027-B2 | Modulators of the NMDA receptor | GRIN1, GRIN2A, GRIN3A | KDM4E 735/4885ALDH1A1 3491/4885POLB 4347/4885 |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | CAMKK2, CAMKK1, CAMK1 | KDM4E 2232/4885ALDH1A1 3614/4885POLB 4147/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | KDM4E 4125/4885ALDH1A1 576/4885POLB 4839/4885 |
| US-20130324528-A1 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 | ALK, ALKBH5, ALKBH3 | KDM4E 135/4885ALDH1A1 134/4885POLB 2615/4885 |
| US-20240059680-A1 | N-(2,3-DIHYDRO-1,4-BENZOXAZIN-4-YL)-3-ISOPROPYL-7-(2,3,5-TRIFLUOROPHENYL)BENZO-THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND SIMILAR COMPOUNDS FOR THE TREATMENT OF HEARTWORM INFECTIONS | TNNT2, TNNI3, SIRT5 | KDM4E 837/4885ALDH1A1 491/4885POLB 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.